Misplaced Pages

Clonitazene: Difference between revisions

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively
Page 1
Page 2
← Previous editContent deleted Content addedVisualWikitext
Revision as of 05:54, 2 September 2011 editBogBot (talk | contribs)Bots53,132 edits populated new fields in {{drugbox}} and reordered per bot approval. Report errors and suggestions to User_talk:BogBot← Previous edit Latest revision as of 23:22, 10 January 2025 edit undoArthurfragoso (talk | contribs)Extended confirmed users, Template editors4,591 edits dark mode fix 
(42 intermediate revisions by 36 users not shown)
Line 1: Line 1:
{{Short description|Opioid analgesic}}
{{Drugbox {{Drugbox
| Verifiedfields = changed | Verifiedfields = changed
| Watchedfields = changed | Watchedfields = changed
| verifiedrevid = 399721174 | verifiedrevid = 447993587
| IUPAC_name = 2--5-nitrobenzimidazol-1-yl]-''N'',''N''-diethylethanamine | IUPAC_name = 2--5-nitrobenzimidazol-1-yl]-''N'',''N''-diethylethanamine
| image = Clonitazene.png | image = Clonitazene.svg
| image_class = skin-invert-image
| width = 180 | width = 180
| image2 = Clonitazene 3D BS.png
| image_class2 = bg-transparent
| width2 = 180


<!--Clinical data--> <!--Clinical data-->
| tradename = | tradename =
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> | pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X --> | pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category = | pregnancy_category =
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> | legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = | legal_BR = A1
| legal_BR_comment = <ref>{{Cite web |author=Anvisa |author-link=Brazilian Health Regulatory Agency |date=2023-03-31 |title=RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial |trans-title=Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control|url=https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 |url-status=live |archive-url=https://web.archive.org/web/20230803143925/https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 |archive-date=2023-08-03 |access-date=2023-08-16 |publisher=] |language=pt-BR |publication-date=2023-04-04}}</ref>
| legal_UK =
| legal_US = | legal_CA = Schedule I
| legal_status = | legal_UK = Class A
| legal_US = Schedule I
⚫ | routes_of_administration =
| legal_DE = Anlage I
⚫ | routes_of_administration =


<!--Pharmacokinetic data--> <!--Pharmacokinetic data-->
| bioavailability = | bioavailability =
| protein_bound = | protein_bound =
| metabolism = | metabolism =
| elimination_half-life = | elimination_half-life =
| excretion = | excretion =


<!--Identifiers--> <!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 3861-76-5 | CAS_number = 3861-76-5
| ATC_prefix = none | ATC_prefix = none
| ATC_suffix = | ATC_suffix =
| PubChem = 62528 | PubChem = 62528
| DrugBank_Ref = {{drugbankcite|changed|drugbank}} | DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01523 | DrugBank = DB01523
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 56301 | ChemSpiderID = 56301
| UNII_Ref = {{fdacite|changed|FDA}} | ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 2104616
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = S90R21A2V2 | UNII = S90R21A2V2
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D12668


<!--Chemical data--> <!--Chemical data-->
| C=20 | H=23 | Cl=1 | N=4 | O=2 | C=20 | H=23 | Cl=1 | N=4 | O=2
| molecular_weight = 386.88 g/mol
| smiles = (=O)c3ccc1c(nc(n1CCN(CC)CC)Cc2ccc(Cl)cc2)c3 | smiles = (=O)c3ccc1c(nc(n1CCN(CC)CC)Cc2ccc(Cl)cc2)c3
| InChI = 1/C20H23ClN4O2/c1-3-23(4-2)11-12-24-19-10-9-17(25(26)27)14-18(19)22-20(24)13-15-5-7-16(21)8-6-15/h5-10,14H,3-4,11-13H2,1-2H3
| InChIKey = GPZLDQAEBHTMPG-UHFFFAOYAT
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} | StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C20H23ClN4O2/c1-3-23(4-2)11-12-24-19-10-9-17(25(26)27)14-18(19)22-20(24)13-15-5-7-16(21)8-6-15/h5-10,14H,3-4,11-13H2,1-2H3 | StdInChI = 1S/C20H23ClN4O2/c1-3-23(4-2)11-12-24-19-10-9-17(25(26)27)14-18(19)22-20(24)13-15-5-7-16(21)8-6-15/h5-10,14H,3-4,11-13H2,1-2H3
Line 51: Line 60:
}} }}


'''Clonitazene''' is an ] ] of approximately three times the potency of morphine.<ref>{{cite journal | vauthors = Hunger A, Kebrle J, Rossi A, Hoffmann K | s2cid = 32179439 | title = | journal = Experientia | volume = 13 | issue = 10 | pages = 400–1 | date = October 1957 | pmid = 13473817 | doi = 10.1007/BF02161116 | url = https://www.scribd.com/doc/78362960/Synthese-basisch-substituierter-analgetisch-wirksamer-Benzimidazol-Derivate-Synthesis-of-analgesically-active-benzimidazole-derivatives-with-basic-s | trans-title = Synthesis of analgesically active benzimidazole derivatives with basic substitutions | url-access = subscription }}</ref> It is related to ], an opioid of significantly higher potency. Clonitazene is not currently marketed. It is a controlled substance; in the United States it is a ] with a DEA ACSCN of 9612 and an established manufacturing quota of 25 grams for 2022.
'''Clonitazene''' is an ] ] of approximately three times the potency of morphine. It is related to ].

==See also==
* ]


== References == == References ==
{{Reflist}}
<references />


{{Opioidergics}}
⚫ ]
]
]
⚫ ]


⚫ ]
⚫ {{Analgesic-stub}}
]
⚫ ]
]



]
⚫ {{Analgesic-stub}}
Clonitazene: Difference between revisions Add topic